KRAS and cancer: Despite the fact that statins and ezetimibe were shown to interfere with several cancer-related processes such as inflammation, cell proliferation, angiogenesis, apoptosis, and metastization, recent studies failed to demonstrate that statins improve CC survival, regardless of KRAS mutation status (17, 18).